Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 102,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · derivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,597 Underlying: Common Stock · 102,597 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F12 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. F12 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 19,043 | $27.57 | $525,015.51 |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,655 F1 · shares: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 171 | $38.61 | $6,602.31 |
DisclosureSEC source: 0001628280-26-005794 · wk-form4_1770326240.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,698 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $38.520 to $38.885, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 646 | $37.82 | $24,433.01 |
DisclosureSEC source: 0001628280-26-005794 · wk-form4_1770326240.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,869 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.490 to $38.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,200 | $39.91 | $127,721.60 |
DisclosureSEC source: 0001628280-26-005794 · wk-form4_1770326240.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,515 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.590 to $40.360, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:15 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,017 | $40.01 | $160,732.22 |
DisclosureSEC source: 0001628280-26-003089 · wk-form4_1769116519.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,715 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.695 to 40.250, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantPerformance-Based Stock Unit · Derivative | 62,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001239501-26-000002 · form4-01142026_040107.xml · derivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,219 Underlying: Common Stock · 62,219 shares Expires not disclosed F11 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F11 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F11 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock | 62,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001239501-26-000002 · form4-01142026_040107.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,732 F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on March 4, 2024 ("2024 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on January 12, 2026. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $40.10 | $53,688.54 |
DisclosureSEC source: 0001628280-26-001161 · wk-form4_1767819973.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,513 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.000 to $40.255, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,678 | $38.09 | $102,005.02 |
DisclosureSEC source: 0001628280-26-001161 · wk-form4_1767819973.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,852 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.970 to $38.450, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 830 | $40.35 | $33,490.50 |
DisclosureSEC source: 0001628280-25-058974 · wk-form4_1767042438.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,530 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.01 to $40.69, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 509 | $40.04 | $20,380.36 |
DisclosureSEC source: 0001628280-25-058249 · wk-form4_1766178398.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,360 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.08, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 12,821 | $38.55 | $494,300.83 |
DisclosureSEC source: 0001628280-25-057651 · wk-form4_1766006402.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,869 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $38.135 to $39.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,012 | $39.30 | $39,775.65 |
DisclosureSEC source: 0001628280-25-057651 · wk-form4_1766006402.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,690 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $39.240 to $39.390, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 18,513 | $38.75 | $717,323.21 |
DisclosureSEC source: 0001628280-25-057651 · wk-form4_1766006402.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,702 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.240 to $39.220, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 15,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · derivative · entry 15 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,424 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F12 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 61,698 RSUs which vest in four equal installments beginning on December 10, 2022. F12 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 61,698 RSUs which vest in four equal installments beginning on December 10, 2022. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 6,070 | $38.02 | $230,781.40 |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,215 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 15,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 33,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · derivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,496 Underlying: Common Stock · 33,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F11 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 133,983 RSUs which vest in four equal installments beginning on December 9, 2023. F11 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 133,983 RSUs which vest in four equal installments beginning on December 9, 2023. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 13,181 | $38.25 | $504,173.25 |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,861 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 33,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056631 · wk-form4_1765496931.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $40.03 | $53,600.17 |
DisclosureSEC source: 0001628280-25-055843 · wk-form4_1765229330.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,547 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.11, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,678 | $39.23 | $105,057.94 |
DisclosureSEC source: 0001628280-25-055348 · wk-form4_1764882481.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.92 to $39.48, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,258 | $40.09 | $170,703.22 |
DisclosureSEC source: 0001628280-25-054431 · wk-form4_1764623340.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,564 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.42, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 19:58 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,115 | $40.05 | $204,850.64 |
DisclosureSEC source: 0001628280-25-054126 · wk-form4_1764187130.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,822 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.000 to $40.165, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,678 | $34.02 | $91,105.56 |
DisclosureSEC source: 0001628280-25-053387 · wk-form4_1763672845.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,937 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.79 to $34.16, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,678 | $31.85 | $85,296.98 |
DisclosureSEC source: 0001628280-25-050169 · wk-form4_1762463255.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,615 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $31.520 to $32.090, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 237 | $31.12 | $7,374.73 |
DisclosureSEC source: 0001628280-25-050169 · wk-form4_1762463255.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,293 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.115 to $31.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,458 | $30.41 | $196,407.15 |
DisclosureSEC source: 0001628280-25-050169 · wk-form4_1762463255.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,530 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.990, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 13:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $22.44 | $30,047.16 |
DisclosureSEC source: 0001628280-25-045995 · wk-form4_1761226243.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,988 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.290 to $22.615, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $22.58 | $30,234.62 |
DisclosureSEC source: 0001628280-25-044297 · wk-form4_1759781506.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,327 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.31 to $23.14, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $21.97 | $29,419.17 |
DisclosureSEC source: 0001628280-25-042152 · wk-form4_1758312308.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,666 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.860 to $22.085, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $23.93 | $32,042.27 |
DisclosureSEC source: 0001239501-25-000010 · wk-form4_1757016249.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,005 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025 F2 · price: This transaction was executed in multiple trades at prices ranging from $23.79 to $24.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,339 | $20.04 | $26,833.56 |
DisclosureSEC source: 0001239501-25-000008 · wk-form4_1755633879.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,344 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to 20.10, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 43,019 | $19.50 | $839,042.58 |
DisclosureSEC source: 0001239501-25-000006 · wk-form4_1755288862.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,683 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.265 to $19.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionPerformance-Based Stock Unit · Derivative | 66,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001239501-25-000003 · wk-form4_1755030736.xml · derivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F11 · derivative.exercise_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F11 · derivative.expiration_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 23,972 | $19.36 | $464,097.92 |
DisclosureSEC source: 0001239501-25-000003 · wk-form4_1755030736.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,702 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 66,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001239501-25-000003 · wk-form4_1755030736.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the transfers on July 11, 2025, of 36,907 shares of common stock from DJM Grantor Annuity Trust No. 5 and 7,416 shares of common stock from DJM Grantor Annuity Trust No. 6 to the Reporting Person's direct holdings, and the transfer on July 14, 2025, of 44,323 shares of common stock from the Reporting Person's direct holdings to DJM Grantor Annuity Trust No. 7. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 660 | $20.30 | $13,398.00 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 3,615 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 660 | $20.30 | $13,398.00 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 3,615 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 660 | $20.30 | $13,398.00 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 3,615 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 660 | $20.30 | $13,398.00 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 3,618 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,924 | $20.30 | $140,557.20 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 44,986 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,068 | $20.30 | $163,780.40 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 52,923 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,944 | $20.30 | $100,363.20 |
DisclosureSEC source: 0001447362-25-000093 · wk-form4_1751400312.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,683 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 165 | $21.52 | $3,550.47 |
DisclosureSEC source: 0001447362-25-000061 · wk-form4_1745438887.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 4,275 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.325 to $21.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 165 | $21.52 | $3,550.47 |
DisclosureSEC source: 0001447362-25-000061 · wk-form4_1745438887.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 4,275 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.325 to $21.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 165 | $21.52 | $3,550.47 |
DisclosureSEC source: 0001447362-25-000061 · wk-form4_1745438887.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 4,275 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.325 to $21.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 165 | $21.52 | $3,550.47 |
DisclosureSEC source: 0001447362-25-000061 · wk-form4_1745438887.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 4,278 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.325 to $21.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,731 | $21.52 | $37,247.66 |
DisclosureSEC source: 0001447362-25-000061 · wk-form4_1745438887.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 51,910 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.325 to $21.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.